Interactions of D600 (methoxyverapamil) and local anesthetics with rat brain α-adrenergic and muscarinic receptors
References (23)
- et al.
Life Sci.
(1976) - et al.
J. biol. Chem.
(1951) - et al.
Biochem. Pharmac.
(1977) - et al.
Gen. Pharmac.
(1976) - et al.
Biochim. biophys. Acta
(1975) Analyt. Biochem.
(1972)A. Rev. Pharmac. Toxic.
(1977)- et al.
Drugs
(1978) - et al.
Pflügers Arch. ges. Physiol.
(1972) - et al.
Post-grad. med. J.
(1974)
Rec. Adv. Stud. cardiac Struct. Metab.
Cited by (107)
Lidocaine: neurobiological targets and effects on the auditory system
2007, Progress in Brain ResearchCitation Excerpt :Lidocaine also inhibited muscarinic receptors of the m1 subtype, the most common subtype in the CNS with an IC50 (18 nM) (Hollmann et al., 2000), which was significantly less than needed for blocking sodium channels. Competitive inhibition in a binding assay showed contrary sensitivity to former results (Fairhurst et al., 1980). Evidence for cholinergic receptor upregulation was found in the DCN of rats in connection with sound-induced plasticity (Kaltenbach and Zhang, 2007).
Structure-activity relationships for substrate recognition by the human dopamine transporter
2004, Biochemical PharmacologyCitation Excerpt :When the test compound and dopamine act at distal sites, both of which are mutually exclusive with WIN 35,428, the presence of a fixed concentration of test compound at its ic50 level can be calculated to actually enhance the potency of dopamine in inhibiting WIN 35,428 binding, i.e. shifting the dopamine curve to the left, rather than merely shifting the dopamine curve to the right less than 2-fold. This has been demonstrated in the classical paper of Fairhurst et al.[27] as well as Huang and Ehrenstein [28] for sodium and calcium channel blockers. The same papers also detail the “intermediate” situation which, as applied to our case, has the test compound compete for the dopamine site in addition to acting at a distal site (with both sites being mutually exclusive with WIN 35,428).
Protection against methoxyacetic-acid-induced spermatocyte apoptosis with calcium channel blockers in cultured rat seminiferous tubules: Possible mechanisms
1997, Toxicology and Applied PharmacologyCalcium channel blockers induce thymic apoptosis in vivo in rats
1996, Toxicology and Applied PharmacologyPharmacology of the Neurotransmitter Release Enhancer Linopirdine (DuP 996), and Insights into Its Mechanism of Action
1996, Advances in Pharmacology
- ∗
Present address: Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, U.S.A.